Pharmacogenetics of antidepressive treatment

The search of the genetic predictors of response to antidepressants is a rapidly expanding field. A large number of clinical studies are reporting partly inconsistent results. Emerging new results focus on new candidate single nucleotide polymorphisms—particularly in the 5HT2a-receptor gene and the...

Full description

Saved in:
Bibliographic Details
Published in:European archives of psychiatry and clinical neuroscience 2010-08, Vol.260 (5), p.407-417
Main Authors: Zobel, Astrid, Maier, Wolfgang
Format: Article
Language:English
Subjects:
Antidepressive Agents - therapeutic use
Brain-Derived Neurotrophic Factor - genetics
Depression - drug therapy
Depression - genetics
Humans
Medicine
Medicine & Public Health
Neurosciences
Original Paper
Pharmacogenetics
Phenotype
Polymorphism, Single Nucleotide - genetics
Psychiatry
Receptor, Serotonin, 5-HT2A - genetics
Serotonin Plasma Membrane Transport Proteins - genetics
Tacrolimus Binding Proteins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The search of the genetic predictors of response to antidepressants is a rapidly expanding field. A large number of clinical studies are reporting partly inconsistent results. Emerging new results focus on new candidate single nucleotide polymorphisms—particularly in the 5HT2a-receptor gene and the gene coding for the co-chaperone FKBP5. The impact of the 5HTTLPR polymorphism on therapeutic outcome and side effects under treatment with SSRIs has to be viewed in a more complex manner than previously proposed. All replicable genetic associations display only a very modest effect. Despite of enormous research efforts, currently pharmacogenetics of therapeutic effects and of side effects of antidepressants are unable to guide decisions on the selection of the most beneficial drug for an individual patient.
ISSN:0940-1334
1433-8491
DOI:10.1007/s00406-009-0091-4